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Abstract
Histamine regulates functions via four receptors (HRH1,
HRH2, HRH3, and HRH4). The D-myo-inositol
1,4,5-trisphosphate (IP3)/Ca
2+/protein kinase C
(PKC)/mitogen-activated protein kinase pathway regulates
cholangiocarcinoma growth. We evaluated the role of
HRH3 in the regulation of cholangiocarcinoma growth.
Expression of HRH3 in intrahepatic and extrahepatic cell
lines, normal cholangiocytes, and human tissue
arrays was measured. In Mz-ChA-1 cells stimulated with
(R)-(α)-(−)-methylhistamine dihydrobromide (RAMH), we
measured (a) cell growth, (b) IP3 and cyclic AMP levels, and
(c) phosphorylation of PKC and mitogen-activated protein
kinase isoforms. Localization of PKCα was visualized by
immunofluorescence in cell smears and immunoblotting for
PKCα in cytosol and membrane fractions. Following
knockdown of PKCα, Mz-ChA-1 cells were stimulated with
RAMH before evaluating cell growth and extracellular
signal–regulated kinase (ERK)-1/2 phosphorylation. In vivo
experiments were done in BALB/c nude mice. Mice were
treated with saline or RAMH for 44 days and tumor volume
was measured. Tumors were excised and evaluated for
proliferation, apoptosis, and expression of PKCα, vascular
endothelial growth factor (VEGF)-A, VEGF-C, VEGF receptor
2, and VEGF receptor 3. HRH3 expression was found in all
cells. RAMH inhibited the growth of cholangiocarcinoma
cells. RAMH increased IP3 levels and PKCα phosphorylation
and decreased ERK1/2 phosphorylation. RAMH induced a
shift in the localization of PKCα expression from the
cytosolic domain into the membrane region of Mz-ChA-1
cells. Silencing of PKCα prevented RAMH inhibition of
Mz-ChA-1 cell growth and ablated RAMH effects on ERK1/2
phosphorylation. In vivo, RAMH decreased tumor growth
and expression of VEGF and its receptors; PKCα expression
was increased. RAMH inhibits cholangiocarcinoma growth
by PKCα-dependent ERK1/2 dephosphorylation. Modulation
of PKCα by histamine receptors may be important in
regulating cholangiocarcinoma growth. (Mol Cancer Res
2009;7(10):1704–13)
Introduction
Cholangiocarcinoma is the secondmost common type of can-
cer in the liver after hepatocellular carcinoma (1). Biliary tract
cancers are challenging to diagnose and treat (1, 2). Chronic in-
flammation and obstruction of bile ducts may play an important
role in the progression of this deadly disease (3). Cholangiocar-
cinoma, once diagnosed, is commonly treated by surgical resec-
tion; however, this option is not always viable (1).
Histamine acts by interacting with four G-protein–coupled
receptors, HRH1, HRH2, HRH3, and HRH4 (4-7); these
four G-protein–coupled receptors exert actions on numerous
G-proteins (8). We have shown that the HRH3 agonist, (R)-
(α)-(−)-methylhistamine dihydrobromide (RAMH), decreases
hyperplastic cholangiocyte growth in bile duct–ligated chole-
static rats by inhibition of cyclic AMP (cAMP)–dependent sig-
naling (6). The actions of RAMH likely occur by activation of
the G-coupled protein, GαI, which inhibits adenylyl cyclase
and consequently cAMP activation (9, 10); however, the H3
histamine receptor can signal through Gαo (11). We have
shown that HRH1 acts on Gαq to mobilize Ca
2+, thus increasing
the proliferation of small mouse cholangiocytes by activation
of the D-myo-inositol 1,4,5-trisphosphate (IP3)/calmodulin-
dependent protein kinase I/cAMP-responsive element binding
protein–dependent signaling pathway (7). Histamine receptors
have also been shown to be involved in the regulation of
numerous cancers (12).
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Protein kinase C (PKC) is a broad family of protein kinases
made up of approximately 10 to 12 isozymes (13). Convention-
al isoforms of the PKC family, including PKCα, PKCβI,
PKCβII, and PKCγ (13), require calcium, diacylglycerol, and
a phospholipid-like phosphatidylcholine for activation. These
conventional PKCs act through the same signal transduction
pathway as phospholipase C (PLC; ref. 13). PKC is involved
in tumor growth (14) and represents a tool for therapeutic strat-
egies in cancer progression. PKCα activation has been shown
to be required for activation of extracellular signal–regulated
kinase (ERK)-1/2 signaling in human lung cancer cells (15).
Without current successful therapies for the treatment of
cholangiocarcinoma, the purpose of this research is to evaluate
the role of the H3 histamine receptor in the regulation of cho-
langiocarcinoma growth.
Results
Receptor Expression
By immunofluorescence, all the cell lines express HRH3; spe-
cific immunoreactivity is shown in red, and the cell nuclei are
counterstained with 4′,6-diamidino-2-phenylindole (Fig. 1A,
blue). Real-time PCR analyses revealed that HRH3 mRNA ex-
pression [expressed as ratio to glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) mRNA] increased in Mz-ChA-1, SG231,
and CCLP-1 compared with H69 cells (Fig. 1B). Immunohisto-
chemical analysis of human liver biopsy samples (using commer-
cially available tissue arrays) showed that there was increased
HRH3 immunoreactivity in cholangiocarcinoma samples com-
pared with control (Fig. 1C). Evaluation of HRH1, HRH2, and
HRH4 by real-time PCR revealed that all cell types express these
receptors (data not shown).
Evaluation of Cholangiocarcinoma Growth
By MTS assay, stimulation with RAMH (5-200 μmol/L) in-
hibited the growth of Mz-ChA-1, HuH-28, and CCLP-1 cells at
24 and 48 hours (Fig. 2A-C). RAMH did not change the
growth of H69 cells (data not shown). 1,2-Bis-(o-aminophe-
noxy)-ethane-N,N,N′,N′-tetraacetic acid, tetraacetoxymethyl
ester (BAPTA/AM), Gö6976, and U73122 blocked the inhibi-
tory effect of RAMH on Mz-ChA-1 cell growth (Fig. 2D), but
alone did not change Mz-ChA-1 cell growth (data not shown).
Treatment of Mz-ChA-1 cells with the specific agonists for
HRH1, HRH2, or HRH4 showed that HRH1 and HRH2 had
slight proliferative effects on Mz-ChA-1 growth, whereas the
HRH4 agonist decreases growth (data not shown).
Effect of RAMH on Intracellular IP3 and cAMP Levels
As RAMH was shown to decrease cholangiocarcinoma
growth at varying concentrations, we chose to use a similar
dose (10 μmol/L) that we have previously used to inhibit the
growth of hyperplastic cholangiocytes (6). RAMH (10 μmol/L)
significantly (P < 0.05) increased intracellular IP3 levels of
Mz-ChA-1 cells compared with their corresponding basal
levels [0.98 ± 0.026 (basal) versus 1.82 ± 0.002 (RAMH)
pmol/1 × 106 cells], but not cAMP levels [144.48 ± 5.6 (basal)
versus 153.48 ± 5.7 (RAMH) fmol/1 × 105 cells]. These results
strengthen the notion that in cholangiocarcinoma cells, the
H3 histamine receptor signals through Gαo, resulting in activa-
tion of a PLC/IP3/Ca
2+–dependent signaling pathway indepen-
dent of cAMP activity.
FIGURE 1. The expression of
HRH3 was measured by immuno-
fluorescence (A), real-time PCR
(B), and tissue array analysis (C).
A. By immunofluorescence, all the
cholangiocarcinoma cell lines used
as well as H69 expressed HRH3;
specific immunoreactivity is shown
in red, and the cell nuclei are coun-
terstained with 4′,6-diamidino-2-
phenylindole (blue). Bar, 50 μm.
B. By real-time PCR, the HRH3
message was increased in cholan-
giocarcinoma cells compared with
normal cells. Columns, mean of
three experiments; bars, SEM. *,
P < 0.05, versus HRH3 mRNA ex-
pression of H69 cells. C. HRH3
immunoreactivity was increased in
cholangiocarcinoma samples com-
pared with control. Original magni-
fication, ×40. Columns, mean of
three experiments; bars, SEM. *,
P < 0.01, versus HRH3 expression
of normal biopsy samples.
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Transduction Pathway Evaluation
RAMH (10 μmol/L) significantly increased the phosphory-
lation of PKCα (Fig. 3A), but not of PKCβI, PKCβII, and
PKCγ (data not shown), in Mz-ChA-1 cells compared with
their corresponding basal values. Total PKCα was similar in
the two treatment groups (Fig. 3A). PKCα is a serine/threonine
kinase and can be activated by numerous tyrosine residues (16).
The serine 643 residue seems to be the autophosphorylation
site, and several tyrosine sites compose the catalytic domain,
which are crucial for activation (16). The antibody that we used
detects PKCα phosphorylation on the serine 657 residue (17).
By immunofluorescence, there was distinct positive staining for
PKCα in bovine serum albumin (BSA)–stimulated (i.e., unsti-
mulated) Mz-ChA-1 cells localized in the cytoplasm of these
cells (Fig. 3B). After RAMH stimulation, there was translo-
cation of PKCα from the cytosolic region into the membrane
domain of the cells (Fig. 3B). This finding was further con-
firmed by immunoblotting for cytosolic and membrane frac-
tions that were extracted (using the Qiagen Qproteome Cell
Compartment kit) from Mz-ChA-1 cells stimulated in the
absence or presence of RAMH (10 μmol/L for 15 minutes).
Figure 3C clearly shows that PKCα expression is increased
in the membrane fraction after RAMH treatment, compared
with the higher basal expression seen in the cytosol fraction.
To confirm that we were successful with the fractionation, we
performed immunoblotting for GAPDH and Bcl2 (18). With
the finding that RAMH induced the phosphorylation/transloca-
tion of PKCα, we sought to pinpoint the role of PKCα activity
in Mz-ChA-1 growth using siRNA transfection. In PKCα
siRNA–transfected cells (∼90% knockdown efficiency;
Fig. 3D, top) treated with RAMH, there was a loss of the in-
hibitory effects of RAMH on Mz-ChA-1 growth compared
with scrambled siRNA– or control-transfected cells (Fig. 3D,
bottom). However, in mock-transfected cells, RAMH
(10 μmol/L) decreased the proliferation (similar to levels
seen in Fig. 2A) of Mz-ChA-1 cells compared with mock-
transfected, basal cells (Fig. 3D, bottom).
RAMH had no effect on the phosphorylation of protein
kinase A (PKA), p38, and c-jun NH2-terminal kinase (data
not shown). However, RAMH decreased the phosphorylation
FIGURE 2. RAMH inhibited Mz-ChA-1 (A), HuH-28 (B), and CCLP-1 (C) growth at 24 and 48 h compared with their corresponding basal levels. Columns,
mean of 12 experiments; bars, SEM. *, P < 0.05, versus the corresponding basal value. D. MTS assays in Mz-ChA-1 cells stimulated with 0.1% BSA or
RAMH (10 μmol/L with 0.1% BSA at 24 h) in the absence or presence of preincubation with BAPTA/AM (5 μmol/L), Gö6976 (1 μmol/L), or U73122 (1 μmol/L).
Pretreatment with BAPTA/AM, Gö6976, and U73122 prevented RAMH-induced inhibition of Mz-ChA-1 growth. *, P < 0.001, versus the corresponding basal
value. Columns, mean of 12 experiments; bars, SEM.
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of the mitogen-activated protein kinase (MAPK), ERK1/2,
compared with its basal value (Fig. 4). Silencing of PKCα
(by siRNA transfection; Fig. 3D, top) ablated the effects
of RAMH on ERK1/2 phosphorylation (Fig. 4), further
confirming the regulatory role of PKCα in RAMH-induced
manipulation of cholangiocarcinoma. Total levels for ERK1/
2 (Fig. 4) were unchanged between basal and RAMH-
stimulated cells.
FIGURE 3. A. Phosphorylation of PKCα was significantly increased in Mz-ChA-1 cells treated with RAMH compared with the corresponding basal values.
*, P < 0.05, versus the corresponding basal value. Columns, mean of six blots; bars, SEM. B. PKCα immunolocalization was shown using immunofluores-
cence. In unstimulated Mz-ChA-1 cells, there is an increased expression of PKCα in the cytosolic region; however, after treatment with RAMH (15 min), there
is a shift in expression that seems to be stronger in the membrane region in Mz-ChA-1 cells, suggesting translocation of PKCα from the cytosol into the
membrane region after RAMH stimulation. Red, PKCα expression; blue, nuclear counterstain [4′,6-diamidino-2-phenylindole (DAPI)]. Nonimmune serum was
used as a negative control. Original magnification, ×60. C. Centrifugal fractionation for cytosol and membrane compartments shows that RAMH (10 μmol/L,
15 min) increases the expression of total PKCα in the membrane compartment compared with basal-treated cell lysates. A representative blot is shown for
GAPDH (indicating the cytosolic fraction), Bcl2 (a control for the membrane fraction), total PKCα, and β-actin (for proper protein loading determination). D.
Top, siRNA silencing for PKCα. Using increasing amounts of siRNA PKCα (0.25-1 μg), there was a significant reduction in PKCα expression as seen by
PKCα immunoblotting compared with scrambled siRNA and control (0.2% BSA). A representative blot is shown normalized with β-actin. Bottom, knockdown
of PKCα using siRNA (1 μg DNA) resulted in the loss of the inhibitory effects of RAMH (10 μmol/L) on Mz-ChA-1 cell growth. Mock-transfected cells stimulated
with RAMH (10 μmol/L) inhibited the growth of Mz-ChA-1 cells compared with mock-transfected, BSA-treated cells. A representative blot is shown normalized
with β-actin. *, P < 0.05, versus the corresponding basal value. Columns, mean of six experiments; bars, SEM.
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Nude Mouse Evaluation
Chronic treatment with RAMH had a significant inhibitory
effect on cholangiocarcinoma growth in vivo. After 44 days,
tumor growth remained relatively unchanged in nude mice trea-
ted with RAMH compared with the vehicle group that in-
creased ∼100% [151 ± 8.9 mm3 to 295.94 ± 15.36 mm3
(days 1-44, vehicle) versus 130.65 ± 12.5 mm3 to 135.06 ±
11.21 mm3 (days 1-44, RAMH)]. Representative pictures from
treated mice and a summary graph of each data point are seen
in Fig. 5A. There was no significant difference between final
body weight, liver weight, and liver-to-body-weight ratio be-
tween vehicle- and RAMH-treated mice (data not shown). His-
tologically, no changes were seen in fibrosis or inflammation in
tumors from either RAMH- or vehicle-treated mice (data not
shown); however, necrosis was significantly upregulated in
RAMH-treated tumors [20.17 ± 1.84 (vehicle) versus 36.88 ±
4.92 (RAMH)] compared with tumors from vehicle-treated
mice. The number of proliferating cell nuclear antigen
(PCNA)–positive cells was decreased in RAMH-treated
animals compared with vehicle-treated mice (Fig. 5B, top),
whereas apoptosis (evaluated by caspase-3 protein expression)
increased in tumors from RAMH-treated compared with
vehicle-treated mice (Fig. 5B, bottom). Compared with in vitro
data for total PKCα that showed no significant difference in
basal versus RAMH-stimulated cells (Fig. 3A), we found that
total PKCα expression was significantly increased in tumors
from RAMH-treated mice compared with vehicle (Fig. 5C).
This result is presumably due to the chronic exposure of
the tumor cells to RAMH compared with the acute effects
seen in vitro. Expression of vascular endothelial growth
factor (VEGF)-A, VEGF-C, VEGF receptor (VEGFR)-2, and
VEGFR-3 was downregulated in tumor samples from
RAMH-treated animals compared with vehicle-treated mice
(Fig. 5D). Quantitative data for all immunohistochemistry
are found in Table 1. Evaluation of other organs showed no
histologic changes in RAMH-treated animals compared with
vehicle (data not shown), indicating that the dosage of RAMH
was not toxic to other organ systems.
Discussion
In this study, we have shown that activation of HRH3 by
RAMH decreases both in vitro and in vivo cholangiocarcinoma
growth via IP3/Ca
2+/PKCα–dependent dephosphorylation of
ERK1/2. In vitro, we showed that (a) HRH3 are upregulated
in cholangiocarcinoma cells and in human tissue arrays com-
pared with normal cells and tissues; (b) RAMH inhibits the
growth of cholangiocarcinoma growth by increased levels of
IP3; further, RAMH induces translocation and enhanced phos-
phorylation of PKCα, which leads to a dephosphorylation of
ERK1/2; and (c) PKCα knockdown prevents RAMH inhibition
of cholangiocarcinoma growth and ERK1/2 phosphorylation.
In vivo, we showed that (a) RAMH inhibits the growth of
Mz-ChA-1 cells implanted in nude mice coupled with
enhanced apoptosis, and (b) RAMH inhibition of cholangiocar-
cinoma growth was associated with enhanced expression
of PKCα and reduced expression of VEGF-A, VEGF-C,
VEGFR-2, and VEGFR-3.
Our present studies correlate with our previous study show-
ing that RAMH decreases the growth of hyperplastic cholan-
giocytes (6). However, whereas RAMH (acting via Gαi)
inhibited hyperplastic biliary growth by inhibition of cAMP-
dependent PKA/ERK1/2/Elk-1 (6), in the present study, RAMH
(acting through Gαo) decreased cholangiocarcinoma growth by
PLC/IP3/Ca
2+/PKCα–dependent inhibition of ERK1/2 phos-
phorylation, which is independent of cAMP activation. It is
FIGURE 4. Phosphoryla-
tion of ERK1/2 was inhibited
by RAMH (10 μmol/L) treat-
ment in mock-transfected
Mz-ChA-1 cells compared with
basal, mock-transfected cells.
After PKCα silencing, there
was a loss of RAMH-induced
ERK1/2 inhibition compared
with basal, PKCα-transfected
cells. A representative blot is
shown. *, P < 0.05, versus
the corresponding basal value.
Columns, mean of six blots;
bars, SEM.
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known that histamine exerts its effects on cells via activation of
the four histamine receptors that couple to diverse G-proteins
(4, 5). Our studies involving hyperplastic (6) along with the
current study show the ability of HRH3 to preferentially couple
to different G-proteins. In cardiac sympathetic nerves, Levi
et al. (19) reported a novel, signaling pathway for the H3 his-
tamine receptor. In this study, they found that HRH3 exerted
its actions via both the GαI-mediated inhibition of adenylyl
cyclase-cAMP-PKA and the Gβγ-mediated activation of a
MAPK-dependent pathway, specifically the MAPK-phospholipase
A2-cyclooxygenase-prostaglandin E2-prostaglandin EP3 receptor
pathway (19). These studies offer evidence that the histamine recep-
tors, including the H3 receptor, are able to diversify their signaling
effects in different cell systems.
To dissect the role of HRH3 in the regulation of cholangio-
carcinoma growth, we evaluated the expression of this receptor
in malignant and normal cell lines. Expression and overexpres-
sion of histamine and histamine receptors have been seen in
other tissues and cell types (12, 20). HRH3 and HRH4 are up-
regulated in human mammary tissue and carcinomas compared
with normal samples (12). Further, in colon carcinoma cells,
HRH1, HRH2, and HRH4 were found to be present (20). We
have previously shown that (a) HRH3 is found in cholangio-
cytes from normal and bile duct–ligated rats (6); and (b) small
and large mouse cholangiocytes express HRH1, HRH2, HRH3,
and HRH4 (7). However, in small cholangiocytes, the HRH1
agonist was the only receptor agonist to induce changes in pro-
liferation (7). These studies are important in understanding the
differential effects of histamine (via the four receptors) in the
proliferative capacity of different cell types, including cholan-
giocarcinoma. Here, the HRH1 and HRH2 agonists elicit stim-
ulatory effects in our cholangiocarcinoma cells, whereas the
HRH4 agonist clobenpropit reduced cell growth (data not
shown), showing an innate ability for histamine to regulate
its effects by activating specific receptors when warranted.
Differential regulation of histamine receptors is found in
many cell types including Leydig cells where there is an inhi-
bitory (via HRH1) and a stimulatory (via HRH3) effect on
FIGURE 5. A. RAMH (10 mg/kg/bw) stunts tumor growth compared with vehicle (0.9% NaCl)–treated mice. Data shown is average tumor values from four
mice (eight tumors in total) for each treatment group. Representative images for vehicle- and RAMH-treated tumors are shown. Points, mean tumor size; bars,
SEM. B. RAMH induces a decrease in the number of PCNA-positive cells coupled with an increase in the number of apoptotic cells compared with vehicle
treatment. Original magnification, ×40. a and c, vehicle; b and d, RAMH. C. PKCα expression increased in tumors from RAMH-treated mice compared with
tumors from vehicle-treated mice. Original magnification, ×20. a, vehicle (0.9% NaCl); b, RAMH (10 mg/kg/bw). D. RAMH decreased the expression of
VEGF-A, VEGF-C, VEGFR-2, and VEGFR-3 compared with vehicle-treated mice. Original magnification, ×20. a and c vehicle; b and d, RAMH. See Table
1 for quantitative data.
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steroidogenesis (21). We have found both a stimulatory (by
HRH1; ref. 7) and an inhibitory (by HRH3; ref. 6) response
in cholangiocyte growth.
The PKC isozymes are important regulators of proliferation,
differentiation, angiogenesis, and apoptosis in a number of cells
including cholangiocytes (22-25). In our study, we have shown
that PKCα plays a key role in RAMH inhibition of cholangio-
carcinoma growth because (a) this HRH3 agonist induces acti-
vation of the PLC/Ca2+/IP3/PKCα signaling pathway; (b)
RAMH inhibitory action is dependent on this signaling path-
way; (c) RAMH induces activation and translocation of PKCα;
and (d) gene silencing of PKCα prevents the inhibitory effects
induced by RAMH including phosphorylation of ERK1/2.
PKCα is important in the regulatory mechanisms of the growth
of many cancers including cholangiocarcinoma (14, 22, 24). A
recent study has shown that activation of PKCα plays an im-
portant role in the cytotoxicity and mutagenicity of human lung
cancer cell lines by changes in Raf-1-MAPK kinase 1/2-ERK1/
2 signaling (15). Inhibition of the human hepatoma cells was
also found to be dependent on PKCα activation, which was
found to signal via the ERK pathway (26). In addition, taurour-
sodeoxycholic acid inhibits human cholangiocarcinoma growth
via Ca2+-PKCα–dependent dephosphorylation of ERK1/2 (22).
These results are consistent with other studies showing that
PKCα is a key player in cancer growth regulation whether
by activation of PKCα or by deactivation of this important
protein (25).
Our next experiments were aimed to evaluate the chronic
effects of RAMH on tumor growth. Using an established pro-
tocol (27), we showed that, in comparison with vehicle-treated
mice, chronic treatment with RAMH (a) decreased tumor
growth and increased apoptosis, (b) significantly increased
PKCα protein expression, and (c) decreased the expression of
the angiogenic factors (VEGF-A and VEGF-C; ref. 28) and
their receptors (VEGFR-2 and VEGFR-3). VEGF proteins
and their receptors are notorious partners in crime with regard
to regulation of cancer growth (29, 30). Upregulation of these
factors has been seen in numerous human cancers including
breast (29) and colorectal (30) cancers. We propose that inhibi-
tion of tumor growth by RAMH is also due to decreased ex-
pression of the trophic factors, VEGF-A and VEGF-C and
their receptors, which are important for the vascularization, de-
velopment, and growth of neoplasias (31). Compounds that are
able to inhibit the expression of VEGF (and its receptors) are
important in decreasing the growth of cancer (27). The growth
of human breast cancer cells was inhibited by treatment with
epigallocatechin-3-gallate, which was coupled with decreased
VEGF expression (32). In hepatocellular carcinoma, rapamycin
decreases tumor growth and angiogenesis via downregulation
of both hypoxia-inducible factor 1α and VEGF (33). These
studies are among just a few that have come to light in recent
years showing the importance of VEGF in cancer growth and
the implications of identifying factors that have the ability to
downregulate VEGF expression.
In summary, we have shown that the specific HRH3 agonist
RAMH inhibits the growth of cholangiocarcinoma cell lines
and tumors implanted into nude mice. This decrease in cholan-
giocarcinoma growth by RAMH is associated with increased
levels of IP3, translocation of PKCα, and IP3/Ca
2+–dependent
dephosphorylation of ERK1/2. Further, RAMH increased
PKCα expression and significantly decreased the expression
of VEGF (and its receptors) in vivo. These studies further
emphasize the importance of histamine in cholangiocyte regu-
lation via activation of the four receptors, whether it is hyper-
plastic or neoplastic cholangiocyte growth.
Whereas novel treatments for cholangiocarcinoma are ac-
tively being sought out, our study shows that curative therapy
may begin with the prevention of tumor growth and by block-
ing the components that aid in the maintenance of the blood
supply that feeds the tumor. A compound such as the H3 his-
tamine receptor agonist may offer new hope as a therapeutic
strategy for patients facing a dismal prognosis.
Materials and Methods
Materials
High-quality reagents were obtained from Sigma unless
indicated otherwise. Antibodies for siRNA, immunoblotting,
immunohistochemistry, and immunofluorescence were pur-
chased from Santa Cruz Biotechnology unless indicated other-
wise. The RIA kits for the measurement of intracellular cAMP
(125I Biotrak Assay System, RPA509) and IP3 (
3H Biotrak
Assay System, TRK1000) levels were purchased from GE
Healthcare. Primers and other reagents for real-time PCR were
obtained from SABiosciences.
Cell Culture. We used a number of intrahepatic and extrahe-
patic cholangiocarcinoma cell lines along with nonmalignant,
immortalized cholangiocytes (H69). Mz-ChA-1 cells from hu-
man gallbladder (24, 34) were a gift of Dr. G. Fitz (University
of Texas Southwestern Medical Center, Dallas, TX). HuH-28
cells (Cancer Cell Repository, Tohoku University) from human
intrahepatic bile duct (35) were maintained as described (24).
CCLP-1 (ref. 36; from intrahepatic bile ducts; from Dr. A.J.
Demetris, University of Pittsburg, Pittsburg, PA) were cultured
as described (36-38). The nonmalignant cholangiocyte cell line,
H69 (from Dr. G.J. Gores, Mayo Clinic, Rochester, MN), was
cultured as described (39).
Receptor Expression
We evaluated HRH3 receptor expression in all cell lines by
(a) immunofluorescence (7, 40), (b) real-time PCR in total
RNA (1 μg; refs. 7, 40), and (c) immunohistochemistry (41)
in commercially available Accumax tissue arrays. We also
Table 1. Quantitative Data for the Expression of PCNA,
Cleaved Caspase-3, PKCα, VEGF-A, VEGF-C, VEGFR-2,
and VEGFR-3 in Nude Mice Treated with Vehicle (0.9%
NaCl) or RAMH (10 mg/kg/bw)
Parameter Vehicle (0.9% NaCl) RAMH (10 mg/kg/bw)
PCNA 33.11 ± 3.29 13.14 ± 1.49*
Cleaved caspase-3 21.80 ± 2.6 41.4 ± 2.71*
PKCα 2.60 ± 0.98 26.80 ± 2.52*
VEGF-A 74.2 ± 2.92 63.4 ± 3.25*
VEGF-C 53.00 ± 3.44 9.83 ± 1.40*
VEGFR-2 66.33 ± 1.67 11.00 ± 3.30*
VEGFR-3 77.60 ± 1.50 30.40 ± 3.26*
NOTE: Values are mean ± SEM of four mice per group.
*P < 0.05 versus vehicle.
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evaluated the expression of HRH1, HRH2, and HRH4 by real-
time PCR (7, 40) in total RNA from the selected cell lines.
Immunofluorescence. For immunofluorescence, cells were
seeded on coverslips in a six-well plate (500,000 per well)
and allowed to adhere overnight. Immunofluorescence was
done as described (40) using the HRH3 receptor antibody (di-
luted 1:50 in 1% BSA/PBST or nonimmune serum). Images
were visualized using an Olympus IX-71 confocal microscope.
Real-time PCR. To evaluate the expression of HRH1,
HRH2, HRH3, and HRH4 mRNA in total RNA (1 μg) from
cholangiocarcinoma cell lines and H69 cells, we used the
RT2 Real-time assay from SABiosciences (6, 7). Human pri-
mers (SABiosciences) were designed for the histamine receptor
subtypes and GAPDH, the housekeeping gene (7, 40). A
ΔΔCT (delta threshold cycle) analysis was done using the
H69 cell line as the control sample.
Human Tissue Array. Immunoreactivity for HRH3 was
evaluated in Accumax tissue arrays by immunohistochemistry
(41) using a specific antibody for HRH3 (6). These tissue ar-
rays contain 48 well-characterized human cholangiocarcinoma
biopsy samples from a variety of tumor differentiation grades
as well as 4 control liver biopsy samples. Semiquantitative
analysis was done as described (41).
Evaluation of Cholangiocarcinoma Growth
MTS Assays. Cells were seeded into 96-well plates and stim-
ulated for 24 and 48 h with the HRH3 agonist, RAMH (ref. 6;
5-200 μmol/L). In separate experiments, we evaluated the
effect of histamine trifluoromethyl toluidide (HTMT dimaleate;
HRH1 agonist, 10 μmol/L; ref. 7), amthamine dihydrobromide
(HRH2 agonist, 10 μmol/L; ref. 42), or clobenpropit (HRH4
agonist, 10 μmol/L; ref. 43) on cholangiocarcinoma growth
for 48 h. Cholangiocarcinoma growth was evaluated by the
CellTiter 96 AQueous One Solution Cell Proliferation Assay
(6, 27, 40). Absorbance was measured at 490 nm on a micro-
plate spectrophotometer (Versamax, Molecular Devices). Data
were expressed as the fold change of treated cells as compared
with vehicle-treated controls.
To evaluate the intracellular mechanisms by which RAMH
regulates cholangiocarcinoma growth, Mz-ChA-1 cells were
stimulated with 0.1% BSA (basal) or RAMH (10 μmol/L with
0.1% BSA, 24 h; ref. 6) in the absence or presence of the
following inhibitors: BAPTA/AM (an intracellular Ca2+ chela-
tor, 5 μmol/L; ref. 24), Gö6976 (a PKCα inhibitor, 1 μmol/L;
ref. 28), and U73122 (a PLC inhibitor; 1 μmol/L; ref. 6).
Growth of Mz-ChA-1 cells was measured by MTS assay
(6, 27, 40).
Effect of RAMH on Intracellular IP3 and cAMP Levels
To evaluate the transduction pathway activated by the
HRH3 agonist, we measured intracellular IP3 (7) and cAMP
(6, 44) levels in Mz-ChA-1 cells stimulated with 0.1% BSA
or RAMH (10 μmol/L with 0.1% BSA). Following trypsini-
zation, Mz-ChA-1 cells were incubated at 37°C for 1 h (22,
45) and subsequently stimulated with 0.1% BSA (basal) or
RAMH (10 μmol/L with 0.1% BSA) for 5 min before deter-
mining intracellular cAMP and IP3 levels by RIA (22, 23,
27, 45).
Effect of RAMH on the Phosphorylation of PKA, PKC, and
MAPK Isoforms
Mz-ChA-1 cells were stimulated with 0.1% BSA or RAMH
(10 μmol/L with 0.1% BSA) for 2 h at 37°C. Following stim-
ulation, we evaluated the expression of the phosphorylated
form (expressed as ratio to the corresponding total protein ex-
pression) of PKA; Ca2+-dependent PKCα, PKCβI, PKCβII,
and PKCγ; and the MAPKs, ERK1/2, c-jun NH2-terminal ki-
nase, and p38, by immunoblots (7). The amount of protein
loaded was normalized by immunoblots for α-tubulin (6). Band
intensity was determined by scanning video densitometry using
the phospho-imager Storm 860 (GE Healthcare) and the Image-
Quant TL software, version 2003.02 (GE Healthcare).
Changes in PKCα Translocation Induced by RAMH
To detect membrane translocation, Mz-ChA-1 cells were
plated, stimulated with 0.1% BSA (basal) or RAMH
(10 μmol/L with 0.1% BSA) for 15 min, and processed for
immunofluorescence (7, 40) as described above using the anti-
body for total PKCα. Negative controls were done with the use
of preimmune serum instead of the respective primary anti-
body. Slides were visualized using an Olympus IX-71 inverted
confocal microscope. To further evaluate the localization of
PKCα in Mz-ChA-1 cytosol and membrane fractions, we per-
formed an extraction for these compartments using the Qiagen
Qproteome Cell Compartment kit followed by immunoblotting
for total PKCα (as described above). Mz-ChA-1 cells were
plated and brought to confluency; 5 × 106 cells were used
per treatment [0.2% BSA (basal) or RAMH (10 μmol/L with
0.1% BSA)] for 15 min. The extraction was done using these
cellular lysates according to the instructions provided by the
vendor. Specifically, sequential addition of different buffers to
the cell pellets was followed by incubation and centrifugation
(at 4°C) at varying speeds allowing for the isolation of different
cellular compartments. The first buffer breaks down the plasma
membrane without solubilizing it, resulting in cytosolic protein
isolation. The remaining compartmentalized organelles and
plasma membrane are left intact and pelleted by centrifugation.
After the addition of the second buffer that solubilizes the
plasma membrane, centrifugation allows for the collection of
membrane proteins (18). After fractionation, we performed
immunoblotting for GAPDH (localized in the cytosol of liver)
and Bcl2 (localized in the membrane region) to confirm sepa-
ration (18). Immunoblotting (6) was then done for total PKCα;
blots were stripped and normalized to β-actin to validate proper
protein loading. Blots were visualized as described above.
Effect of PKCα Silencing on RAMH Modulation of
Mz-ChA-1 Cell Growth
To evaluate the effects of PKCα on cholangiocarcinoma
growth, we used siRNA to knock down the expression of
PKCα and evaluated cholangiocarcinoma growth by PCNA
protein expression and the phosphorylation of ERK1/2 by im-
munoblotting analysis (6, 23). Mz-ChA-1 cells were plated into
six-well plates and allowed to adhere overnight. siRNA trans-
fection (0.25-1 μg of PKCα siRNA was used) was done
according to the instructions provided by Santa Cruz Biotech-
nology. Diluted siRNA duplexes were added to the cells and
allowed to incubate for 5 h at 37°C in a CO2 incubator. For
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controls, a scrambled siRNA duplex (obtained from Santa Cruz
Biotechnology) was added to corresponding wells. The extent
of PKCα silencing was evaluated by measuring the expression
of total PKCα in transfected versus control Mz-ChA-1 cells by
immunoblotting for PKCα (6, 7). PCNA and phosphorylated
ERK1/2 protein expression was evaluated in Mz-ChA-1 cells
stimulated with 0.1% BSA or RAMH (10 μmol/L with 0.1%
BSA) for 24 h in the absence or presence of PKCα siRNA
(1 μg).
Effect of RAMH on Cholangiocarcinoma Tumor Implanted
in Nude Mice
Treatment Schedule. Eight-week-old male BALB/c nude
(nu/nu) mice (∼30 grams in weight; Taconic Farms) were kept
in a temperature-controlled environment (20-22°C) with a
12-h light-dark cycle with access to drinking water and stan-
dard chow. Mz-ChA-1 cells (3 × 106) were suspended in
0.5 mL of extracellular matrix gel and injected s.c. in the flanks
of these animals (27). The first group of mice (n = 4; control)
received 0.9% NaCl injections i.p. (150 μL), whereas the sec-
ond group (n = 4) received RAMH (10 mg/kg body weight in
NaCl; 150 μL; ref. 46), injected i.p., for 44 d. The injections
were done every other day starting from “day 0,” when the
tumors were implanted, for 44 d. Tumor parameters were
measured twice a week by an electronic caliper, and volume
was determined as follows: tumor volume (mm3) = 0.5 ×
[length (mm) × width (mm) × height (mm)]. The measurements
started from the 3rd week, day 23, when the tumor mass was
well established. After 44 d, mice were anesthetized with sodi-
um pentobarbital (50 mg/kg i.p.) and tissues harvested. All
experiments were conducted under the guidelines of the Scott
& White and Texas A&M Health Science Center Institutional
Animal Care and Use Committee. Along with tumor excision,
samples for the heart, liver, and kidney were removed for eval-
uation of organ damage.
Morphologic Analysis of Tumor Tissues. Tumor samples
were excised from the flanks of the mice, fixed in 10% buffered
formalin for 2 to 4 h, and embedded in low-temperature fusion
paraffin, and 4-μm sections were stained with H&E (for eval-
uation of necrosis and inflammation) and Masson's trichrome
(for evaluation of fibrosis). Immunohistochemistry was done as
described (28) using primary antibodies for cytokeratin-7,
PCNA, cleaved caspase-3, total PKCα, and VEGF-A and
VEGF-C (two trophic factors regulating cholangiocyte growth;
ref. 28) and their receptors, VEGFR-2 and VEGFR-3. For all
immunoreactions, negative controls were also included. Light
microscopy and immunohistochemistry observations were
taken using a BX-51 light microscope (Olympus) with a video-
cam (Spot Insight, Diagnostic Instrument, Inc.) and evaluated
with an Image Analysis System (Delta Sistemi). Quantitation
was assessed in six slides for each group. Positive cells were
counted in six nonoverlapping fields for each slide, and the
data expressed as percentage of positive cells.
Statistical Analysis
All data are expressed as mean ± SEM. Differences between
groups were analyzed by the Student unpaired t test when two
groups were analyzed and by ANOVA when more than two
groups were analyzed, followed by an appropriate post hoc test.
P value of <0.05 was used to indicate statistical significance.
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